In response to the FDA’s historic decision, the Drug Enforcement Administration (DEA) announced in September 2018 that it had removed Epidiolex from Schedule I classification, a category reserved for dangerous drugs with no medical value. Henceforth, Epidiolex would be considered a Schedule V drug, the least dangerous designation under the Controlled Substances Act.
Thanks for your interest in our products. Unfortunately due to strict FDA regulations I am unable to make claims on our products based on your specific needs, I can though share our top selling products in each category. Please view the links below:http://cbdoilreview.org/product/elixinol-cbd-oil-extract-x-pen-1000mg/http://cbdoilreview.org/product/endoca-hemp-oil-drops-1500mg/http://cbdoilreview.org/product/elixinol-hemp-oil-drops-regular-300mg/http://cbdoilreview.org/product/elixinol-cbd-hemp-oil-capsules-900mg/https://cbdoilreview.org/product/vape-bright-thrive-cbd-vape-cartridge-200mg/As far as dosage goes, I would recommend reading through our page on dosing. I have attached that link below. https://cbdoilreview.org/cbd-cannabidiol/cbd-dosage/Hopefully these help.
In fact, the U.S. Food and Drug Administration (FDA) approved Epidiolex (a drug made with a purified form of CBD oil) in June 2018 for the treatment of seizures associated with two rare and severe forms of epilepsy in patients 2 years of age and older. These two epilepsy forms are known as Lennox-Gastaut syndrome and Dravet syndrome. Epidiolex is the first FDA-approved drug that contains a purified drug substance derived from marijuana.